Outlook Therapeutics Inc
OTLK
查看详细走势图
0.429USD
+0.039+10.10%
收盘 02/06, 16:00（美东）报价延迟15分钟
23.14M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+10.10%
5天
-2.34%
1月
-27.22%
6月
-76.66%
今年开始到现在
-72.82%
1年
-74.89%
查看详细走势图
TradingKey Outlook Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Outlook Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业中等水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名200/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.38。中期看，股价处于下降通道。近一个月，市场表现非常差，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
Outlook Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Outlook Therapeutics Inc亮点
亮点风险
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
业绩增长期
公司处于发展阶段，最新年度总收入1.41M美元
估值高估
公司最新PE估值-0.24，处于3年历史高位
机构减仓
最新机构持股4.34M股，环比减少70.98%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值1.47M
活跃度增加
近期活跃度增加，过去20天平均换手率0.63
分析师目标
根据
4
位分析师
买入
评级
5.375
目标均价
+1243.75%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Outlook Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Outlook Therapeutics Inc简介
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
公司代码OTLK
公司Outlook Therapeutics Inc
CEOJahr (Robert Charles)
网址https://outlooktherapeutics.com/
相关品种
